Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doripenem prolonged-infusion monotherapy for empirical treatment of febrile neutropenia
2011-000533-36Phase 2Active
- Sponsor
- Grupo Español de Trasplante Hematopoyético
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doripenem in febrile neutropenia (FN), sponsored by Grupo Español de Trasplante Hematopoyético. Primary endpoint: Target serum doripenem exposure above MIC thresholds. Started Jan 2012; status: active.
02
Drugs
doripenem
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on 2011-000533-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000533-36.